Managing anaplastic thyroid carcinoma

Ejigayehu G. Abate, Robert Christian Smallridge

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Anaplastic thyroid cancer is one of the most lethal malignancies, with dismal prognosis, resistance to multimodal treatments and a median survival of only 5-6 months. Advances in the discovery of genetic pathway aberrations involved in this aggressive disease have been made, and multiple novel therapies targeting these pathways are undergoing clinical trials. So far, there is no single effective treatment for this disease; however, multimodal therapies with a combination of surgery, radiation and chemotherapy hold some promise. We conducted a PubMed search using the words thyroid neoplasm, anaplastic thyroid carcinoma, anaplastic thyroid cancer and anaplastic thyroid neoplasm, revealing 1673 publications. We review the pathophysiology, current treatments and advances made in identifying the alterations in genetic pathways, as well as novel therapies targeting these pathways.

Original languageEnglish (US)
Pages (from-to)793-809
Number of pages17
JournalExpert Review of Endocrinology and Metabolism
Volume6
Issue number6
DOIs
StatePublished - Nov 2011

Fingerprint

Thyroid Neoplasms
Therapeutics
Combined Modality Therapy
PubMed
Publications
Anaplastic Thyroid Carcinoma
Clinical Trials
Radiation
Drug Therapy
Neoplasms

Keywords

  • anaplastic thyroid carcinoma
  • multimodal treatments
  • novel therapy
  • pathogenesis
  • signaling pathways
  • staging
  • targeted therapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Managing anaplastic thyroid carcinoma. / Abate, Ejigayehu G.; Smallridge, Robert Christian.

In: Expert Review of Endocrinology and Metabolism, Vol. 6, No. 6, 11.2011, p. 793-809.

Research output: Contribution to journalArticle

@article{6274624b7231470c97b466cb7a356d18,
title = "Managing anaplastic thyroid carcinoma",
abstract = "Anaplastic thyroid cancer is one of the most lethal malignancies, with dismal prognosis, resistance to multimodal treatments and a median survival of only 5-6 months. Advances in the discovery of genetic pathway aberrations involved in this aggressive disease have been made, and multiple novel therapies targeting these pathways are undergoing clinical trials. So far, there is no single effective treatment for this disease; however, multimodal therapies with a combination of surgery, radiation and chemotherapy hold some promise. We conducted a PubMed search using the words thyroid neoplasm, anaplastic thyroid carcinoma, anaplastic thyroid cancer and anaplastic thyroid neoplasm, revealing 1673 publications. We review the pathophysiology, current treatments and advances made in identifying the alterations in genetic pathways, as well as novel therapies targeting these pathways.",
keywords = "anaplastic thyroid carcinoma, multimodal treatments, novel therapy, pathogenesis, signaling pathways, staging, targeted therapy",
author = "Abate, {Ejigayehu G.} and Smallridge, {Robert Christian}",
year = "2011",
month = "11",
doi = "10.1586/eem.11.76",
language = "English (US)",
volume = "6",
pages = "793--809",
journal = "Expert Review of Endocrinology and Metabolism",
issn = "1744-6651",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Managing anaplastic thyroid carcinoma

AU - Abate, Ejigayehu G.

AU - Smallridge, Robert Christian

PY - 2011/11

Y1 - 2011/11

N2 - Anaplastic thyroid cancer is one of the most lethal malignancies, with dismal prognosis, resistance to multimodal treatments and a median survival of only 5-6 months. Advances in the discovery of genetic pathway aberrations involved in this aggressive disease have been made, and multiple novel therapies targeting these pathways are undergoing clinical trials. So far, there is no single effective treatment for this disease; however, multimodal therapies with a combination of surgery, radiation and chemotherapy hold some promise. We conducted a PubMed search using the words thyroid neoplasm, anaplastic thyroid carcinoma, anaplastic thyroid cancer and anaplastic thyroid neoplasm, revealing 1673 publications. We review the pathophysiology, current treatments and advances made in identifying the alterations in genetic pathways, as well as novel therapies targeting these pathways.

AB - Anaplastic thyroid cancer is one of the most lethal malignancies, with dismal prognosis, resistance to multimodal treatments and a median survival of only 5-6 months. Advances in the discovery of genetic pathway aberrations involved in this aggressive disease have been made, and multiple novel therapies targeting these pathways are undergoing clinical trials. So far, there is no single effective treatment for this disease; however, multimodal therapies with a combination of surgery, radiation and chemotherapy hold some promise. We conducted a PubMed search using the words thyroid neoplasm, anaplastic thyroid carcinoma, anaplastic thyroid cancer and anaplastic thyroid neoplasm, revealing 1673 publications. We review the pathophysiology, current treatments and advances made in identifying the alterations in genetic pathways, as well as novel therapies targeting these pathways.

KW - anaplastic thyroid carcinoma

KW - multimodal treatments

KW - novel therapy

KW - pathogenesis

KW - signaling pathways

KW - staging

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=80054867613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054867613&partnerID=8YFLogxK

U2 - 10.1586/eem.11.76

DO - 10.1586/eem.11.76

M3 - Article

AN - SCOPUS:80054867613

VL - 6

SP - 793

EP - 809

JO - Expert Review of Endocrinology and Metabolism

JF - Expert Review of Endocrinology and Metabolism

SN - 1744-6651

IS - 6

ER -